Zoetis Inc. (NYSE:ZTS) Shares Sold by Janus Henderson Group PLC

Janus Henderson Group PLC lessened its holdings in Zoetis Inc. (NYSE:ZTS) by 9.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,606,508 shares of the company’s stock after selling 164,552 shares during the period. Janus Henderson Group PLC owned approximately 0.36% of Zoetis worth $261,756,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Mission Wealth Management LP increased its holdings in shares of Zoetis by 2.0% in the fourth quarter. Mission Wealth Management LP now owns 2,938 shares of the company’s stock worth $479,000 after buying an additional 59 shares during the period. VeraBank N.A. increased its holdings in shares of Zoetis by 4.1% in the fourth quarter. VeraBank N.A. now owns 1,562 shares of the company’s stock worth $254,000 after buying an additional 62 shares during the period. HUB Investment Partners LLC increased its holdings in shares of Zoetis by 4.7% in the fourth quarter. HUB Investment Partners LLC now owns 1,373 shares of the company’s stock worth $224,000 after buying an additional 62 shares during the period. Procyon Advisors LLC increased its holdings in Zoetis by 1.4% during the 4th quarter. Procyon Advisors LLC now owns 4,712 shares of the company’s stock valued at $768,000 after purchasing an additional 63 shares during the period. Finally, Coppell Advisory Solutions LLC increased its holdings in Zoetis by 18.0% during the 4th quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company’s stock valued at $68,000 after purchasing an additional 64 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Stifel Nicolaus reduced their price target on Zoetis from $180.00 to $165.00 and set a “buy” rating on the stock in a report on Monday, April 14th. UBS Group reduced their price target on Zoetis from $189.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday, May 7th. Morgan Stanley reduced their price target on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. StockNews.com upgraded Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. Finally, Piper Sandler boosted their price target on Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a report on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $212.13.

Zoetis Stock Performance

Zoetis stock opened at $159.96 on Monday. The stock’s 50 day simple moving average is $157.27 and its two-hundred day simple moving average is $165.95. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The stock has a market cap of $71.37 billion, a price-to-earnings ratio of 29.24, a PEG ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $200.33.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The firm had revenue of $2.22 billion for the quarter, compared to analysts’ expectations of $2.20 billion. During the same period in the previous year, the firm posted $1.38 EPS. The business’s revenue for the quarter was up 1.4% compared to the same quarter last year. As a group, analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Insider Transactions at Zoetis

In related news, Director Willie M. Reed sold 1,210 shares of the company’s stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the transaction, the director now directly owns 11,245 shares of the company’s stock, valued at approximately $1,868,244.30. This represents a 9.71% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $170.00, for a total value of $55,420.00. Following the completion of the transaction, the executive vice president now directly owns 15,781 shares in the company, valued at $2,682,770. This trade represents a 2.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,862 shares of company stock valued at $312,254 in the last ninety days. 0.18% of the stock is currently owned by corporate insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.